EssilorLuxottica has entered into an agreement with MidEuropa to acquire Optegra Eye Health Care, a European ophthalmology platform operating across five key markets. The transaction, expected to close in 2025 pending regulatory approvals, represents a significant expansion of EssilorLuxottica's medical technology strategy into comprehensive eye care services.
Strategic Acquisition Expands Clinical Capabilities
The acquisition brings together EssilorLuxottica's global vision care leadership with Optegra's clinical excellence across more than 70 eye hospitals and diagnostic facilities. Operating under the Optegra, Lexum, and Iris brands, the network spans the United Kingdom, Czech Republic, Poland, Slovakia, and the Netherlands.
"With the acquisition of Optegra, we are stepping into a new frontier – one where comprehensive eye care, advanced diagnostics, therapeutic interventions, and surgical treatments come together in one seamless platform," commented Francesco Milleri, chairman and CEO, and Paul du Saillant, deputy CEO at EssilorLuxottica.
Comprehensive Treatment Portfolio with AI Integration
Optegra's facilities provide a full spectrum of ophthalmic treatments and elective vision correction procedures, supported by artificial intelligence in pre- and post-operative stages. The treatment portfolio includes cataract surgery, age-related macular degeneration and glaucoma treatments, refractive lens replacement, and laser eye surgery.
The integration of AI technologies throughout the patient journey represents a key differentiator for the combined platform. EssilorLuxottica executives highlighted their growing AI and big data capabilities as enablers for delivering personalized and seamless patient experiences.
Advanced Diagnostic Capabilities Beyond Vision Care
The acquisition positions EssilorLuxottica to expand beyond traditional vision correction into broader health diagnostics. The company's leadership emphasized diagnostic capabilities that will detect conditions ranging from neurodegenerative diseases to cardiovascular dysfunction, leveraging smart eyewear technology with healthcare potential.
"We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with health care potential, and diagnostic capabilities," the EssilorLuxottica executives stated.
Strategic Growth Under MidEuropa Partnership
Under MidEuropa's ownership, Optegra accelerated its organic expansion and successfully entered two new markets – the Netherlands and Slovakia. The investment firm supported the opening of new clinics in the UK and completed eight strategic add-on acquisitions across five countries.
"Optegra's evolution under MidEuropa's ownership reflects our approach to supporting high-quality European health care platforms with strong growth potential," said Robert Knorr, managing partner at MidEuropa.
Leadership Vision for Integrated Eye Care
Peter Byloos, MD, CEO of Optegra Eye Health Care, described the partnership as a "transformative chapter" that will redefine ophthalmic services paradigms. "Their global leadership in vision care, combined with our clinical excellence and patient-centric approach, creates an innovative platform to redefine the paradigm of ophthalmic services," Byloos stated.
The acquisition creates opportunities for Optegra's clinical team and staff to participate in a global vision care platform while maintaining focus on advanced, digital, and integrated eye care solutions for patients across European markets.
